Bortezomib (the active ingredient in Velcade) is a first-in-class antineoplastic agent known as a reversible proteasome inhibitor. It works by specifically targeting and blocking the activity of "proteasomes"—the cellular machinery responsible for breaking down damaged or excess proteins. In cancer cells, particularly those in the bone marrow, inhibiting this process causes an accumulation of toxic proteins, leading to cell cycle arrest and "programmed cell death" (apoptosis). Because cancer cells are more dependent on rapid protein turnover than healthy cells, Bortezomib effectively stops tumor growth while sparing more stable tissues.
In Nigeria, Bortezomib 3.5mg is a cornerstone clinical choice for advanced blood cancer therapy. It is available through registered specialist pharmacies like Sanlive Pharmacy to ensure oncology centers receive authentic, high-purity lyophilized (freeze-dried) powder manufactured under strict sterile conditions and stored in light-protected, temperature-controlled environments to maintain the molecular integrity of the 3.5mg dose.
Important: This is a high-alert, hospital-only chemotherapy medication. The "Route" Rule: Bortezomib must only be administered intravenously (IV) or subcutaneously (SC). The "Fatal" Warning: Intrathecal administration (into the spine) is fatal and strictly prohibited. The "Neuropathy" Note: This drug can cause nerve damage; your oncologist will monitor you for numbness or tingling in the hands and feet. Do not use if you have a known hypersensitivity to boron or mannitol.
Bortezomib 3.5mg Injections are primarily used to:
Treat Multiple Myeloma (a cancer of the plasma cells in the bone marrow)
Treat Mantle Cell Lymphoma (an aggressive type of non-Hodgkin lymphoma)
Provide a potent therapeutic option for patients who have already received at least one prior therapy
Act as a "Sensitizer" in combination with other drugs like Dexamethasone or Thalidomide
Reduce the "tumor burden" in patients preparing for a stem cell transplant
Induce rapid remission in patients with aggressive B-cell malignancies
This product is suitable for:
Adults diagnosed with Multiple Myeloma, either as a first-line treatment or for relapsed cases
Patients with Mantle Cell Lymphoma whose cancer has returned after previous treatments
Individuals requiring a targeted therapy that works differently from traditional "cytotoxic" chemotherapy
Not recommended for: Children and adolescents (safety and efficacy not established). It is strictly contraindicated for patients with severe acute pericardial or pulmonary disease. Use with extreme caution in patients with pre-existing "peripheral neuropathy" or severe liver impairment. Consult the attending oncologist if the patient is pregnant; Bortezomib is "Teratogenic" and can cause significant harm to a developing fetus.
Administered strictly by a healthcare professional in a specialized oncology unit or infusion center
Reconstitution: The 3.5mg powder must be dissolved with 0.9% Sodium Chloride (Saline) to the exact concentration required for the chosen route (IV or SC)
Standard Cycle: Usually administered twice weekly for two weeks, followed by a ten-day rest period (a 21-day cycle)
SC Administration: Usually injected into the thigh or abdomen; the injection site must be rotated for every dose to prevent skin irritation
IV Administration: Given as a 3 to 5-second bolus injection; it does not require a long infusion
Frequent blood tests (Complete Blood Count and Liver Function) are mandatory before every cycle to monitor for low platelets (thrombocytopenia)
Bortezomib is a powerful targeted therapy, and patients may experience:
Fatigue, weakness, and general malaise (very common)
Nausea, diarrhea, vomiting, or constipation
Peripheral Neuropathy (tingling, burning, or numbness in the limbs)
Thrombocytopenia (low platelet count, which increases the risk of bruising/bleeding)
Anemia and Neutropenia (increased risk of infection)
Loss of appetite and dehydration
Rare but serious: Heart failure or lung inflammation
Rare: "Tumor Lysis Syndrome" (a rapid breakdown of cancer cells that affects the kidneys)
Seek immediate medical attention if the patient develops a fever, unusual bleeding, shortness of breath, sudden swelling of the feet, or severe pain/numbness in the hands and feet.
Reputable specialized oncology pharmaceutical firms – These manufacturers ensure the high-purity stabilization of the Bortezomib molecule to guarantee consistent anti-tumor activity and sterile delivery.
100% authentic oncology medication—guaranteed original and non-counterfeit stock
Guaranteed sterile, light-protected vials stored in optimal, climate-controlled conditions
Professional support for oncology departments on managing specialized chemotherapy logistics
Fast and secure delivery to your hospital, cancer center, or clinic across Nigeria
Is the injection in the skin (SC) better than the one in the vein (IV)?
Many doctors now prefer the subcutaneous (SC) injection because it is just as effective but often causes less nerve damage (neuropathy) and fewer side effects compared to the IV version.
Do I need to take other medicines with this?
Yes. Most patients take an antiviral (like Aciclovir) to prevent shingles, as Bortezomib can weaken your immune system. You may also be prescribed Dexamethasone (a steroid) to make the Bortezomib work better.
What should I do if my hands start tingling?
Tell your oncology nurse or doctor immediately. This is a common side effect, and they may need to adjust your dose or change the way the medicine is given to prevent permanent nerve damage.
Where can I purchase Bortezomib 3.5mg in Nigeria?
Hospitals and specialist oncology clinics can source verified Bortezomib through Sanlive Pharmacy & Stores for guaranteed product integrity and professional pharmaceutical support.
No reviews yet.
Login to write a review.
Related Products
.jpg)
